Investor Presentaiton

Top-tier talent Differentiated process Scalable platform TA agnostic investment approach follows best opportunities Selected investment themes of interest looking forward Under-innovated large markets New modalities for new diseases e.g. migraine e.g. cell and gene therapy, gene editing ROYALTY PHARMA TA: therapeutic area; HCM: hypertrophic cardiomyopathy Brain disease Targeted therapy beyond oncology e.g. mood disorders, neurodegeneration e.g. cardiology (HCM), immunology 66 99

View entire presentation